| | Trials | | WMD (95% CI) | P value |
| | LWDHW plus sustained-release nifedipine versus sustained-release nifedipine | 1 | −10.00 (−11.76, −8.24) | <0.00001 | | LWDHW plus nifedipine controlled release tablet versus nifedipine controlled release tablet | 1 | −10.50 (−24.07, 3.07) | 0.13 | | LWDHW plus captopril versus captopril | 1 | −9.00 (−13.66, −4.34) | 0.0002 | | LWDHW plus nifedipine controlled release tablet versus nifedipine controlled release tablet | 1 | −8.00 (−11.35, −4.65) | <0.00001 | | LWDHW plus nifedipine versus nifedipine | 1 | −3.00 (−10.91, 4.91) | 0.46 |
| | Meta-analysis | 5 | −9.31 (−10.75, −7.86) | <0.00001 |
|
|